Current stock page

Stock Analysis

Biohaven Ltd. (BHVN) Stock Analysis

Biohaven Ltd. (BHVN) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

BHVN Stock Analysis Summary

Biohaven Ltd. (BHVN) currently has an AIQ Score of 47/100, indicating a bearish setup. Momentum is the strongest factor at 78/100. Quality is the weakest current factor at 16/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

BHVN at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$13.82
AIQ Score47/100
Overall ViewBearish
Technical Analysis ConsensusSell
Market Cap$2.09B
P/E Ratio (TTM)-3.58
Forward P/E—
EPS (Q3 FY2026)-$0.86
Revenue (Q3 FY2026)$0
Dividend Yield (TTM)0.00%
Beta1.28
Volume1.26M
52-week range$7.78-$18.24
RSI 1447.8
50-Day SMA$13.52
200-Day SMA$12.33
Analyst Price Target$29.50
Next EarningsMar 1, 2027
As of Nov 13, 2026 · Market close

BHVNBiohaven Ltd.

Healthcare / Biotechnology

Relative Leader / Watch

Strong Relative Position

BearishEdge 8/10
$13.82−$0.25 (−1.78%)

Latest quote

  • Momentum
    78
  • Value
    —
  • Quality
    16
  • Risk resilience
    35
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

BHVN Stock Analysis Summary

Biohaven Ltd. (BHVN) currently has an AIQ Score of 47/100, indicating a bearish setup. Momentum is the strongest factor at 78/100. Quality is the weakest current factor at 16/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bearish

In a bearish regime, BHVN has AIQ Score of 47/100 with Momentum base of 78/100 and fading Quality at 16/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Momentum (78/100) leads while Quality (16/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -1.78% stock move · BHVN classified in Biotechnology.

Current Evidence

BearishBHVN is in a bearish AIQ regime; Momentum is the strongest visible factor at 78/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is BHVN Bullish or Bearish Right Now?

BHVN currently has a bearish overall setup. Momentum is the strongest factor at 78/100, while Quality is weakest at 16/100. The current evidence suggests a bearish setup.

Bull Case
  • - Momentum is constructive at 78/100.
  • - Price is +2.21% above its 50-day SMA.
  • - Analyst target implies +113.46% upside from the latest quote.
Bear Case
  • - Risk Resilience is weak at 35/100.
  • - Technical consensus has more sell votes than buy votes (26 vs 15).

Current Consensus

BHVN's Technical Analysis Consensus is currently Sell, with 15 buy, 5 neutral, and 26 sell votes. BHVN's 14-day RSI is 47.8, which places the stock in a neutral momentum range. BHVN's beta is 1.28, indicating greater market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in BHVN?

The largest recent change in BHVN is Momentum moving down by 2.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
-1.0
Momentum
-2.0
Quality
+0.0
Risk
+0.0

What Would Change the BHVN Outlook?

The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

BHVN Decision Framework

Public evidence layers, setup checks, and risk context for Biohaven Ltd..

Biohaven Ltd. (BHVN) Stock Analysis

Biohaven Ltd. has an AIQ Score of 47/100 in a Bearish regime. Momentum is strongest at 78/100. Beta is 1.28, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextBHVN is in a Bearish AIQ regime with score 47/100.
Signal ConflictThe primary conflict is that momentum leads at 78/100 while quality lags at 16/100.
Factor EvidenceMomentum 78/100 · Quality 16/100 · Risk 35/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Momentum is the strongest factor at 78/100.

TimingPass

Momentum is 78/100 and RSI (14) is 47.8.

Regime fitFail

BHVN is in a Bearish regime at 47/100.

Risk controlFail

Risk factor is 35/100 with beta 1.28 and annual volatility 82.98%.

ConflictWait

Current conflict: momentum leads at 78/100 while quality lags at 16/100.

AIQ Score
47/100
Price
$13.82
Beta
1.28
RSI (14)
47.8

BHVN Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

BHVN Fundamentals

BHVN valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$0
Net income
-$129.28M
Free cash flow
-$107.03M
View full BHVN fundamental analysis

BHVN Technical Analysis

BHVN technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Sell
RSI 14
47.8
Price vs SMA-50
+2.21%
View full BHVN technical analysis

BHVN Stock Catalysts

Track BHVN earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Mar 1, 2027
Analyst target
$29.50
News items
0
View BHVN earnings and stock catalysts

BHVN Dividend Analysis

BHVN dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View BHVN dividend history and analysis

BHVN Financial Data

BHVN revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$0
EPS
-$0.86
Periods
8
View BHVN financials

BHVN Risk Analysis

BHVN volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.28
Risk score
35/100
1Y volatility
82.98%
View BHVN risk analysis

BHVN Stock News

BHVN stock news, market tone, recent headlines, and catalyst context.

News items
0
Updated
—
Sentiment
—
Read BHVN stock news

BHVN vs Biotechnology Peers

Current peer cohort: BHVN · BLTE · CAI · CAPR · CELC. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
BHVN
Current stock
47/100—78/10035/100182.98%Current
BLTE
Belite Bio, Inc
74/100—71/10060/1000.953.71%BHVN vs BLTE
CAI
Caris Life Sciences, Inc.
70/10068/10085/10036/1000.2269.82%BHVN vs CAI
CAPR
Capricor Therapeutics, Inc.
38/100—45/10016/1000.93395.16%BHVN vs CAPR
CELC
Celcuity Inc.
41/100—24/10034/100-0.1963.58%BHVN vs CELC
Pairwise Compare links: BLTE · CAI · CAPR · CELCBHVN vs BLTEBHVN vs CAIBHVN vs CAPRBHVN vs CELCCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a BHVN stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for BHVN: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-3.58
As of Nov 13, 2026
Revenue growth
—
Gross margin
0.00%
Current debt / equity
-3.06
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$0
Quarter net income
-$129.28M
Quarter free cash flow
-$107.03M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bullish
Momentum
Mixed
RSI 14
47.8
MACD
0.37

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
35/100
Beta
1.28
Annual volatility
82.98%
Max drawdown
-41.21%

BHVN Stock FAQ

What is BHVN stock price today?

Biohaven Ltd.'s current stock price is $13.82. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is BHVN bullish or bearish right now?

BHVN's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is BHVN's market cap?

BHVN's market cap is $2.09B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is BHVN's current P/E ratio?

BHVN's current P/E ratio is -3.58 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is BHVN's RSI?

BHVN's 14-day RSI is 47.8 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is BHVN above its 50-day and 200-day moving averages?

BHVN is 2.21% from its 50-day SMA and 12.11% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is BHVN's next earnings date?

BHVN's next earnings date is currently listed as Mar 1, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does BHVN pay a dividend?

BHVN's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.